| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses | 200 | |||
| Cash | 1,761 | |||
| Accounts receivable, related party | 177,147 | |||
| Total current assets | 179,108 | |||
| Investment securities, related party | 17,733 | |||
| Total assets | 196,841 | |||
| Notes payable-Related Party | 266,339 | |||
| Derivative liability | 1,780,402 | |||
| Other current liabilities | 21,000 | |||
| Notes payable-Nonrelated Party | 0 | |||
| Unearned income - related party | 1,370,251 | |||
| Accrued expenses | 1,774,158 | |||
| Accounts payable | 30,477 | |||
| Convertible notes payable, net of unamortized debt discount | 769,905 | |||
| Total current liabilities | 6,012,532 | |||
| Total liabilities | 6,012,532 | |||
| Retained earnings (deficit) | -21,119,151 | |||
| Preferred stock, value-Series APreferred Stock | 1,011 | |||
| Preferred stock, value-Series NCPreferred Stock | 2 | |||
| Preferred stock, value-Series MPreferred Stock | 3 | |||
| Preferred stock, value-Series AAPreferred Stock | 0 | |||
| Preferred stock, value | 0 | |||
| Common stock (.0001 par value) 5,800,000,000 authorized and 31,554,704 and 5,258,235 shares issued and outstanding, respectively | 3,157 | |||
| Additional paid in capital | 15,504,134 | |||
| Other comprehensive income | -204,847 | |||
| Total stockholders equity (deficit) | -5,815,691 | |||
| Total liabilities & stockholders equity (deficit) | 196,841 | |||
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)